Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19

Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19

Abstract Background The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause among patients with COVID-19 at high risk of disease progression. Patient-reported outcomes are important...

Full description

Bibliographic Details
Main Authors: Sacha Satram, Parima Ghafoori, Carolina M. Reyes, Tom J. H. Keeley, Helen J. Birch, Dimitra Brintziki, Melissa Aldinger, Elizabeth Alexander, Amanda Lopuski, Elias H. Sarkis, Anil Gupta, Adrienne E. Shapiro, John H. Powers
Format: Article
Language:English
Published: SpringerOpen 2023-09-01
Series:Journal of Patient-Reported Outcomes
Subjects:
COVID-19
FLU-PRO Plus
Monoclonal antibody
Patient-reported outcomes
PRO
Sotrovimab
Online Access:https://doi.org/10.1186/s41687-023-00621-8

Internet

https://doi.org/10.1186/s41687-023-00621-8

Similar Items